Vestal Point Capital, LP Cytokinetics Inc Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
A detailed history of Vestal Point Capital, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Vestal Point Capital, LP holds 2,075,000 shares of CYTK stock, worth $107 Million. This represents 8.38% of its overall portfolio holdings.
Number of Shares
2,075,000
Previous 2,150,000
3.49%
Holding current value
$107 Million
Previous $151 Billion
25.42%
% of portfolio
8.38%
Previous 12.47%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
407Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$755 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$589 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$419 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$387 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$337 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.85B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...